Buy Opdivo (Nivolumab). Are you looking for a revolutionary cancer treatment that harnesses the power of your immune system? Look no further than Opdivo, also known as Nivolumab. In this article, we will explore the incredible benefits of Opdivo and how it is changing the landscape of cancer treatment.
What is Opdivo (nivolumab) for?
Opdivo is a groundbreaking immunotherapy drug that works by blocking the PD-1 protein on the surface of T-cells, allowing the immune system to recognize and attack cancer cells. This innovative approach has shown remarkable results in patients with various types of cancer, including lung cancer, melanoma, and renal cell carcinoma.
Opdivo (nivolumab) is used to treat several types of cancer. It works well for:
metastatic melanoma as a single agent or in combination with ipilimumab
metastatic non-small cell lung cancer (NSCLC) whose cancer progressed on or after chemotherapy
advanced renal cell carcinoma who have received prior anti-angiogenic therapy
classical Hodgkin lymphoma that has relapsed or progressed after other treatments
recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or within 6 months of receiving platinum-based chemotherapy
locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy
microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
hepatocellular carcinoma in patients who have been previously treated with sorafenib
for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).
How does Opdivo (nivolumab) work?
Opdivo (nivolumab) works by attaching to a receptor called PD-1. This receptor is on T cells, a part of the immune system. Cancer cells can make proteins that block this receptor, stopping T cells from working.
By attaching to PD-1, nivolumab stops cancer cells from blocking T cells. This lets the immune system attack and kill cancer cells more effectively.
Is Opdivo (nivolumab) approved?
Opdivo (nivolumab) was approved by
PMDA (Japan)
on June 2014 for unresectable malignant melanoma
on December 17, 2015, for NSCLC
on August 5, 2016, for unresectable or metastatic renal cell carcinoma
on October 17, 2016, for relapsed or refractory classical Hodgkin lymphoma
on February 22, 2017, for recurrent or distant metastatic head and neck cancer
on August 22, 2017, for unresectable advanced or recurrent gastric cancer that has progressed after cancer chemotherapy.
May 27, 2021, for unresectable advanced or recurrent malignant pleural mesothelioma.
FDA (USA)
on December 22, 2014, for unresectable or metastatic melanoma
on March 4, 2015, for metastatic squamous non-small cell lung cancer (NSCLC)
on November 23, 2015, for advanced renal cell carcinoma
on May 17, 2016, for classical Hodgkin lymphoma (cHL)
on November 10, 2016, for head and neck squamous cell carcinoma (HNSCC)
on February 2, 2017, for advanced unresectable or metastatic urothelial carcinoma
on August 1, 2017, for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer
on September 22, 2017, for hepatocellular carcinoma (HCC) following prior treatment with sorafenib
on December 20, 2017, for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection
on May 20, 2021 as adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer
EMA (EU)
on June 19, 2015, for metastatic melanoma
on July 20, 2015, for NSCLC
on February 26, 2016, for advanced renal cell carcinoma
on October 13, 2016, for relapsed or refractory cHL
on June 2, 2017, for urothelial carcinoma
Health Canada on September 25, 2015 for:
previously untreated unresectable or metastatic BRAF V600 wild-type melanoma
unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor
melanoma with regional lymph node involvement, in transit metastases/satellites without metastatic nodes, or distant metastases, as adjuvant therapy after complete resection
locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy
advanced or metastatic renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy
intermediate/poor-risk advanced or metastatic RCC when used in combination with ipilimumab
recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) progressing on or after platinum-based therapy.
TGA (Australia)
on January 11, 2016, for the metastatic melanoma and NSCLC, and later for advanced clear cell renal cell and relapsed or refractory cHL.
Medsafe (New Zealand) on April 28, 2016, for:
unresectable or metastatic melanoma or melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection
locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after prior chemotherapy
relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant and treatment with brentuximab vedotin
recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy
locally advanced unresectable or metastatic urothelial carcinoma after prior platinum-containing therapy
hepatocellular carcinoma after prior sorafenib therapy.
How do I take Opdivo (nivolumab)?
The recommended therapy varies for different indications. It depends on whether nivolumab is used alone or with other treatments. For detailed information on nivolumab dosage and administration, see the official prescribing information in our references section. Buy Opdivo (Nivolumab)
Note: Consult your treating doctor for personalised dosing.
Are there any known adverse reactions of Opdivo (nivolumab)?
Optimized by Seraphinite Accelerator